English
Back
Download
Log in to access Online Inquiry
Back to the Top

Institutions are buying quietly.

$Vir Biotechnology (VIR.US)$ Only fools would sell. I added it to the risk control limit, it's a pity. The company's pipeline alone is worth 30-50. The existing order is worth 5 yuan. GSK can easily add another 5 yuan with any deal.
The current approach is to discuss the acquisition. Estimated acquisition at 70?
GSK took 20K in Canada. Multiply by 2100. 41M, sigh...
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
3
See Original
Report
14K Views
Comment
Sign in to post a comment
个人投资观点。没有FINRA执照,不代表供职的机构或客户(反正我看不到)。不提供投资建议。临时改个名,免得被citadel找麻烦
285
Followers
20
Following
1984
Visitors
Follow
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.